A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.
A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.
